Ipsen Biopharmaceuticals, Inc.
650 E Kendall Street
About Ipsen Biopharmaceuticals, Inc.
Ipsen (Euronext: IPN; ADR: IPSEY) is a global, biopharmaceutical group focused on innovation and specialty care. The group develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Diseases. At Ipsen, we focus our resources, investments and energy on discovering, developing and commercializing new therapeutic options to provide hope for patients whose lives are challenged by difficult-to-treat diseases. Ipsen's North American operations and headquarters are located in Cambridge, Massachusetts, where our fully integrated biopharmaceutical team across External Innovation and Partnering, Research & Development (R&D), Manufacturing and Commercial collaborate. Cambridge is home to Ipsen's third global hub, in addition to R&D centers in Paris-Saclay in France and Oxford in the United Kingdom. With additional offices in Basking Ridge, N.J. and Mississauga, Ontario, Ipsen employs approximately 600 people in North America. For more information on Ipsen in North America, please visit www.ipsenus.com or www.ipsen.ca.
464 articles with Ipsen Biopharmaceuticals, Inc.
Ipsen and BioLabs to open new Innovation Center in Cambridge (U.S.) to foster development of new therapies for patients
Ipsen Innovation Center – BioLabs to be located in Ipsen’s new and third global hub in the heart of Cambridge, Massachusetts
Ipsen announces new clinical data to be presented at ISPRM 2018 demonstrating commitment to neurotoxin research
Ipsen announced that its neurotoxin portfolio will be the subject of 13 abstracts at the 12th International Society of Physical and Rehabilitation Medicine World Congress.
Trial results formed the basis of regulatory filings in the U.S. and European Union for CABOMETYX® for previously treated advanced hepatocellular carcinoma (HCC)
It’s not exactly breaking news that in the U.S., the two top spots for biotech companies are Boston and San Francisco. But now there’s even more weight to that statement, as French company Ipsen announced it plans to relocate its U.S. operations from New Jersey to Kendall Square in Cambridge, Mas...
Global Biopharmaceutical Company, Ipsen Announces New Headquarters for North America will be located in Cambridge, Massachusetts
Today, Ipsen (Euronext: IPN; ADR: IPSEY), announced it will establish its North American headquarters in Cambridge, Massachusetts.
Ipsen announces that it has appointed an investment services provider to purchase 250,000 Ipsen SA shares, or about 0.30% of the share capital, over a period of at least 3 months.
IPSEN: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to Be Approved at the Combined Shareholders’ Meeting on 30 May 2018 (14th Resolution)
The preliminary notice of meeting including the agenda and the draft resolutions has been published in the Bulletin des Annonces Légales Obligatoires (BALO) on 20 April 2018 and the notice of meeting in the BALO on 9 May 2018.
May 30, 2018 16:00 UTC Adoption of all resolutions submitted to the vote of Shareholders PARIS--( BUSINESS WIRE )-- Regulatory News: The Combined Shareholders’ Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY), chaired by Marc de Garidel, Chairman of the Board, was held today, in the presence of the members of the Board of Directors and the Group’s Executive Management team. The Shareholders’ Meet
Ipsen (Euronext: IPN; ADR: IPSEY), and The University of Texas MD Anderson Cancer Center today announced a global licensing and joint development agreement for a pre-clinical oncology drug candidate.
European Commission approves Ipsen’s Cabometyx® (cabozantinib) for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission (EC) has approved Cabometyx® (cabozantinib) 20, 40, 60 mg for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma (aRCC).
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its sales for the first quarter of 2018.
Ipsen Announces Efficacy and Safety Data for Dysport® (abobotulinumtoxinA) Across Multiple Therapeutic Uses at the 2018 Annual Meeting of the American Academy of Neurology
Analyses of Pooled Data of Dysport® for the Treatment of Pediatric Lower Limb Spasticity Indicate a Consistent Safety Profile
Ipsen Announces EMA Validation of Filing of a New Application for Additional Indication for Cabometyx®, for Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC)
Ipsen announced that the European Medicines Agency (EMA), the European regulatory authority, has validated the filing of a new application for an additional indication for Cabometyx®, for patients with previously treated advanced Hepatocellular Carcinoma (HCC).
Exelixis’ Partner Ipsen Announces EMA Validation of the Application for a New Indication for CABOMETYX® (cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma
Exelixis, Inc. announced that its partner Ipsen received validation of the application for variation to the CABOMETYX® (cabozantinib) marketing authorization from the European Medicines Agency (EMA) for the addition of a new indication for patients with previously treated advanced hepatocellular carcinoma (HCC).
Ipsen Receives Positive CHMP Opinion for Cabometyx® (cabozantinib) for the First-Line Treatment of Adults with Intermediate- or Poor- Risk Advanced Renal Cell Carcinoma
Cabozantinib is the first and only monotherapy to demonstrate superior clinical efficacy over sunitinib in treatment-naïve patients with intermediate- or poor-risk aRCC.
Ipsen announced the appointment of two key executive positions in its Executive Leadership Team.
Merrimack Pharmaceuticals announced it is expanding enrollment in a Phase II lung cancer study.
Arix Bioscience and Ipsen Sign a Strategic Agreement to Develop and Commercialise Innovative Therapies
Arix Bioscience and Ipsen Sign a Strategic Agreement to Develop and Commercialize Innovative Therapies
Ipsen Delivers Strong 2017 Results with 21.1%1 Sales Growth and Core Operating Margin Increase of 3.4 Points and Expects Significant Further Growth in Sales and Margin in 2018
Full Year 2017 Group sales growth of 21.1%1 driven by Specialty Care sales growth of 25.9%1 reflecting continued Somatuline momentum and increasing contribution from the Cabometyx and Onivyde® launches, and Consumer Healthcare back to growth at 1.4%.
Ipsen Announces Dysport (abobotulinumtoxinA) Data Presentations Highlighting Duration of Response and Potential Benefit of Repeated Treatment in Spasticity
Ipsen announced Dysport (abobotulinumtoxinA) data will be presented today in two oral presentations at the annual meeting of the Association of Academic Physiatrists (AAP) being held in Atlanta, February 13-17, 2018.